Nurix Therapeutics, Inc. (NRIX)
22.14
-0.21
(-0.94%)
USD |
NASDAQ |
Oct 12, 16:00
22.52
+0.38
(+1.72%)
After-Hours: 17:32
Nurix Therapeutics Price to Book Value : 5.702 for Oct. 12, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 5.756 |
| October 08, 2026 | 5.720 |
| October 07, 2026 | 5.854 |
| October 06, 2026 | 5.821 |
| October 05, 2026 | 5.893 |
| October 02, 2026 | 5.921 |
| October 01, 2026 | 6.012 |
| September 30, 2026 | 6.107 |
| September 29, 2026 | 6.098 |
| September 28, 2026 | 6.096 |
| September 25, 2026 | 5.926 |
| September 24, 2026 | 6.091 |
| September 23, 2026 | 6.151 |
| September 22, 2026 | 6.612 |
| September 21, 2026 | 6.545 |
| September 18, 2026 | 6.552 |
| September 17, 2026 | 6.568 |
| September 16, 2026 | 6.478 |
| September 15, 2026 | 6.395 |
| September 14, 2026 | 6.573 |
| September 11, 2026 | 6.465 |
| September 10, 2026 | 6.648 |
| September 09, 2026 | 6.764 |
| September 08, 2026 | 6.730 |
| September 04, 2026 | 6.733 |
| Date | Value |
|---|---|
| September 03, 2026 | 6.522 |
| September 02, 2026 | 6.650 |
| September 01, 2026 | 6.707 |
| August 31, 2026 | 6.640 |
| August 28, 2026 | 6.751 |
| August 27, 2026 | 6.922 |
| August 26, 2026 | 6.880 |
| August 25, 2026 | 6.941 |
| August 24, 2026 | 6.766 |
| August 21, 2026 | 6.882 |
| August 20, 2026 | 6.967 |
| August 19, 2026 | 7.158 |
| August 18, 2026 | 6.936 |
| August 17, 2026 | 6.998 |
| August 14, 2026 | 6.967 |
| August 13, 2026 | 7.003 |
| August 12, 2026 | 6.859 |
| August 11, 2026 | 6.686 |
| August 10, 2026 | 6.666 |
| August 07, 2026 | 6.576 |
| August 06, 2026 | 6.496 |
| August 05, 2026 | 6.47 |
| August 04, 2026 | 6.359 |
| August 03, 2026 | 5.981 |
| July 31, 2026 | 5.978 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Gilead Sciences, Inc. | 15.78 |
| ACADIA Pharmaceuticals, Inc. | 2.557 |
| Alnylam Pharmaceuticals, Inc. | 22.42 |
| Anika Therapeutics, Inc. | 2.015 |
| Savara, Inc. | 6.913 |
Price to Book Value Related Metrics
| PS Ratio | 60.28 |
| PEG Ratio | -0.2008 |
| Price | 22.14 |
| Earnings Yield | -15.57% |
| Market Cap | 2.296B |
| PEGY Ratio | -0.2008 |